Hi , Today we announce an exciting new conference keynote speaker, our latest Spotlight episode (hey, Amyris!), huge recognition for our friends at EnginZyme and much more!
Listen: Built with Biology Spaces
Join us today for the Built with Biology show on Twitter Spaces at 8 am PT! Spaces is an audio-only platform—all you need is a Twitter handle and the Twitter app on your phone.
Today’s guests include Janice Chen from Mammoth Biosciences!
We are so excited to announce that renowned investor Cathie Wood will join our all-star IN-PERSON lineup! Get your tickets here!
Listen: Built with Biology Spotlight—Amyris
What do beauty and sharks have in common? Almost 3 millions sharks are killed every year so their livers can be harvested for beauty and skincare ingredients. But what if biology had a better solution? This week, we’re giving a huge shout out to Amyris and Biossance for protecting sharks and our skin, all with engineered biology! Click here to listen to this week’s episode!
EnginZyme Selected as a 2021 Technology Pioneer
Congratulations to our friends at EnginZyme who were recently selected by the World Economic Forum as one of the 2021 Technology Pioneers! EnginZyme is taking on one of the biggest challenges of our time—how to sustainably produce the chemicals, foods, and materials that modern society relies on. “We are extremely honoured to be acknowledged by such a globally respected organisation,” said Karim Engelmark Cassimjee, CEO and co-founder of EnginZyme. Here at SynBioBeta, we’re excited to see how EnginZyme can positively impact our climate crisis!
Science News
Move over, gene-editing proteins – there’s a smaller, cheaper, more specific genetic engineering tool on the block: DNAzymes – small DNA molecules that can function like protein enzymes.
Bacteria – yes, bacteria – could be the key to recycling EV batteries: Here's what you need to know about 'bioleaching'.
A team from Japan and the United States has identified the design principles for creating large "ideal" proteins from scratch, paving the way for the design of proteins with new biochemical functions.
Funding News
Codex DNA closes $122.7 million IPO. Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA.
Jacob Becraft, cofounder and CEO of Strand Therapeutics, wants to take mRNA therapeutics to the next level by using synthetic mRNA to fight tumors. His company just raised a $52 million oversubscribed Series A, and plans to have its first therapy in the clinic by 2022.
ZymoChem awarded $4.2 million from ARPA-E for transformational biomanufacturing technology: Through its proprietary biomanufacturing technology, ZymoChem aims to expedite decarbonization of the chemical industry.
As Ginkgo Bioworks prepares to make its public debut, its co-founders revisit the 13-year journey that led to a $15 billion valuation.
